- GlobeNewswire•10 days ago
BEVERLY, Mass., April 19, 2017-- Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory and antibiotic applications, ...
- GlobeNewswire•19 days ago
Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease
BEVERLY, Mass., April 10, 2017-- Cellceutix Corporation,. Accelerating Phase 2 trial for the Prevention of Severe Oral Mucositis Annual Global Market for SOM may be in the hundreds of millions of dollars. ...
- American City Business Journals•26 days ago
A New York federal judge declined to impose sanctions against a Manhattan law firm that pursued a failed fraud case against Beverly-based Cellceutix based in part on negative blog posts written by an anonymous short-seller. The complaint was filed in September 2015, about one month after the investor website Seeking Alpha published an article about Cellceutix by a short seller using the pseudonym Mako Research. The article questioned the scientific basis of Cellceutix’s drugs and said that it appeared to be a “shell company” run out an empty office building.
CTIX : Summary for CELLCEUTIX CORP COM STK USD0.00 - Yahoo Finance
Cellceutix Corporation (CTIX)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.71 - 0.75|
|52 Week Range||0.66 - 1.87|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|